List view / Grid view
28 September 2015 | By Victoria White
The combination also demonstrated significant health-related quality of life improvements, including overall health, physical and social functioning...
25 September 2015 | By Victoria White
The CHMP’s recommendation is based primarily on results of a Phase III study that showed that people who received the combination of Cotellic and Zelboraf lived over a year without their disease worsening...
7 September 2015 | By Victoria White
NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...
27 August 2015 | By Nick Jackson
New treatment option for patients with difficult-to-treat form of skin cancer has shown improved treatment outcomes...
27 July 2015 | By Victoria White
The CHMP has adopted a positive opinion for the combination of Tafinlar and Mekinist for the treatment of adult patients with advanced melanoma...
23 July 2015 | By Victoria White
The EMA has validated two type II variation applications which seek to extend the indication of Opdivo in non-squamous NSCLC and advanced melanoma...
23 July 2015 | By Victoria White
The EC has approved Merck’s Keytruda (pembrolizumab) for the treatment of advanced (unresectable or metastatic) melanoma in adults...
22 July 2015 | By Victoria White
A Phase III study of selumetinib in combination with dacarbazine for the treatment of metastatic uveal melanoma failed to meet its primary endpoint...
24 June 2015 | By Victoria White
Researchers who analysed more than 20,000 medical records concluded that erectile dysfunction drugs, such as Viagra, are not a cause of melanoma...
23 June 2015 | By Victoria White
Data presented at ASCO 2015 suggests that the Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape...
22 June 2015 | By Victoria White
The European Commission has approved Bristol-Myers Squibb’s Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced melanoma in adults...
2 June 2015 | By Victoria White
The FDA has accepted the supplemental Biologics License Application for Opdivo+Yervoy regimen in patients with previously untreated advanced melanoma...
2 June 2015 | By Victoria White
Encouraging results have been announced from a Phase 1/2 trial of SCIB1, a DNA ImmunoBody being developed for the treatment of patients with melanoma...
1 June 2015 | By Victoria White
BMS has announced positive results of a Phase III trial evaluating the Opdivo+Yervoy regimen in patients with previously untreated advanced melanoma...
30 April 2015 | By Victoria White
The FDA has accepted for filing and review the sBLA for Opdivo for the treatment of previously untreated patients with unresectable or metastatic melanoma...
